French Anti-Obesity Drug Faces Obstacles
PARIS, Oct. 31 — Sanofi-Aventis, the French pharmaceutical company, said today that it could not set a timetable for introducing its new anti-obesity
drug Acomplia in the United States and warned of regulatory obstacles
facing the drug in Germany. The announcement added to the uncertainty
over the drug, a potential blockbuster that analysts say is pivotal to
the company’s future.
Hanspeter Spek, Sanofi’s
executive vice president for pharmaceutical operations, said today that
the company had submitted new information about Acomplia to the United
States Food and Drug Administration
on Oct. 26. He said that though the agency had not called for new
clinical trials of the drug, it was not clear whether it would rule on
the drug soon.
http://www.nytimes.com/
Blogged with Flock
This entry was posted on
October 31, 2006 at 11:17 pm and is filed under Uncategorized.
